Australia's Neuren Pharmaceuticals extends plunge on regulatory hurdles
05/02/2026 02:51
** Shares of Neuren Pharmaceuticals NEU.AX plunges as much as 10.7% to A$13.06 ** Biotech says FDA will only provide written responses for NNZ-2591 drug development meetings, not face-to-face discussions as requested ** Drug targets hypoxic ischemic encephalopathy and Pitt Hopkins syndrome ** Stock fell 10% on Feb 3 on setback for Rett treatment drug application from European regulator, trading halt on Feb 4 pending FDA update (Reporting by Nichiket Sunil in Bengaluru) ((Nichiket.Sunil@thomsonreuters.com))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union